Cited by 106Medication Adherence and ComplianceDiabetes Treatment and ManagementDiabetes Management and Education

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Lack of Treatment Persistence and Treatment Nonadherence as Barriers to Glycaemic Control in Patients with Type 2 Diabetes

Open access

Guerci, Bruno, Chanan, Neha, Kaur, Simarjeet, Jasso-Mosqueda, Juan Guillermo, Lew, Elisheva·2019·Diabetes Therapy

DOI 10.1007/s13300-019-0590-xPMC PMC6437240

Open this paper in CoChat — free account Open PDF

Abstract

Treatment persistence (continuing to take medication for the prescribed period) and treatment adherence (complying with the prescription in terms of drug schedules and dosage) are both important when treating chronic diseases such as type 2 diabetes (T2D). They can be indicators of patient satisfaction with treatment. In T2D, the achievement of optimal outcomes requires both persistence with and adherence to prescribed therapy. Poor persistence with and adherence to T2D medication can have profound consequences for the patient, including non-achievement of glycaemic goals and an increased risk of long-term complications and mortality. Therefore, poor treatment persistence and adherence may also have economic consequences, including increased healthcare resource utilization and healthcare costs. Treatment persistence and adherence are affected by several factors, including the mode of administration, administration frequency/regimen complexity, and patient expectations. The aims of this review are as follows: to provide an overview of persistence with and adherence to different antidiabetes therapies for patients with T2D in the real-world setting; examine factors contributing to poor treatment persistence and adherence; and assess available data on the impact of poor treatment persistence and/or adherence on clinical and economic outcomes. Numerous potential targets for improving treatment persistence and/or adherence are identified, including developing less complex treatment regimens with lower pill burdens or less frequent injections, improving the convenience of drug-delivery systems, such as the use of insulin pen devices rather than the conventional vial and syringe, and developing therapies with an improved safety profile to alleviate patient fears of adverse effects, such as weight gain and risk of hypoglycaemia.Funding: Sanofi.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s13300-019-0590-x

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Medication compliance and persistence: terminology and definitions
Cramer, J. A., Roy, A., Burrell, A., Fairchild, C. J., Fuldeore, M. J., Ollendorf, D. A., & Wong, P. K. (2008) · Value in Health · doi:10.1111/j.1524-4733.2007.00213.x · Cited by 2,220
Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost
Sokol, M. C., McGuigan, K. A., Verbrugge, R. R., & Epstein, R. S. (2005) · Medical Care · doi:10.1097/01.mlr.0000163641.86870.af · Cited by 1,729
Adherence to Therapies in Patients with Type 2 Diabetes
García‐Pérez, L., Álvarez, M., Dilla, T., Gil-Guillén, V. F., & Orozco‐Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 783
Diabetes Attitudes, Wishes and Needs second study (DAWN2™): cross-national benchmarking of diabetes-related psychosocial outcomes for people with diabetes
Nicolucci, A., Kovacs Burns, K., Holt, R. I. G., Comaschi, M., Hermanns, N., Ishii, H., Kokoszka, A., Pouwer, F., Skovlund, S. E., Stuckey, H., et al. (2013) · Diabetic Medicine · doi:10.1111/dme.12245 · Cited by 739
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M. A., Peters, A. L., Τσάπας, Α., Wender, R. C., & Matthews, D. R. (2015) · Diabetologia · doi:10.1007/s00125-014-3460-0 · Cited by 701
Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655
Real‐world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review
Davies, M. J., Gagliardino, J. J., Gray, L. J., Khunti, K., Mohan, V., & Hughes, R. (2013) · Diabetic Medicine · doi:10.1111/dme.12128 · Cited by 302
6. Glycemic Targets
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc17-s009 · Cited by 279
Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: An analysis of third-party managed care claims data
Lee, W. C., Balu, S., Cobden, D., Joshi, A. V., & Pashos, C. L. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.10.004 · Cited by 262

Show all 65 references

Research works printed but not linked: 1

Reynolds SL, Zhou S, Uribe C, Li Y. Impact of insulin delivery systems in elderly patients with type 2 diabetes. Am J Pharm Benefits. 2015;7:222–31.

Sorted by citations

Evolution of Insulin Delivery Devices: From Syringes, Pens, and Pumps to DIY Artificial Pancreas
Kesavadev, J., Saboo, B., Krishna, M. B., & Krishnan, G. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00831-z · Cited by 221
Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration
Okada, M., Mitchell, P., Finger, R. P., Eldem, B. M., Talks, J. S., Hirst, C., Paladini, L. M., Barratt, J., Wong, T. Y., & Loewenstein, A. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.07.060 · Cited by 212
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Tan, Q., Akindehin, S. E., Orsso, C. E., Waldner, R. C., DiMarchi, R. D., Müller, T. D., & Haqq, A. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.838410 · Cited by 146
Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review
Evans, M., Engberg, S., Faurby, M. D., Fernandes, J. D. D. R., Hudson, P., & Polonsky, W. H. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14603 · Cited by 105
Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study)
Polonsky, W. H., ARORA, R., Faurby, M. D., Fernandes, J. D. D. R., & Liebl, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01189-6 · Cited by 85
Oral semaglutide in type 2 diabetes
Anderson, S. L., Beutel, T. R., & Trujillo, J. M. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107520 · Cited by 83
Global, regional, and national cascades of diabetes care, 2000–23: a systematic review and modelling analysis using findings from the Global Burden of Disease Study
Stafford, L. K., Gage, A. D., Xu, Y. Y., Conrad, M., Beltrán, I., Boyko, E. J., Duncan, B. B., Hay, S. I., Lenox, H., Lozano, R., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00217-7 · Cited by 81
Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting
Uzoigwe, C., Liang, Y. M., Whitmire, S. M., & Paprocki, Y. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01053-7 · Cited by 72
Basal weekly insulins: the way of the future!
Rosenstock, J., & Prato, S. D. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154924 · Cited by 63
Real-World Evaluation of GLP-1 Receptor Agonist Therapy Persistence, Adherence and Therapeutic Inertia Among Obese Adults with Type 2 Diabetes
Palanca, A., Ampudia-Blasco, F. J., Calderón, J. M., Sauri, I., Martinez-Hervás, S., Trillo, J. L., Redón, J., & Real, J. T. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01382-9 · Cited by 48
Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?
Kim, H. S., & Jung, C. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189936 · Cited by 41
Understanding Reasons for Treatment Discontinuation, Attitudes and Education Needs Among People Who Discontinue Type 2 Diabetes Treatment: Results from an Online Patient Survey in the USA and UK
Roborel de Climens, A., Pain, E., Boss, A., & Shaunik, A. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00843-9 · Cited by 38
Smart Insulin Pens: Advancing Digital Transformation and a Connected Diabetes Care Ecosystem
Kompala, T., & Neinstein, A. B. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820984490 · Cited by 38
Adherence and persistence to insulin therapy in people with diabetes: impact of connected insulin pen delivery ecosystem
Steenkamp, D., Eby, E. L., Gulati, N., & Liao, B. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/1932296821997923 · Cited by 33
Insulin Therapy for the Management of Diabetes Mellitus: A Narrative Review of Innovative Treatment Strategies
Nkonge, K. M., Nkonge, D. K., & Nkonge, T. N. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01468-4 · Cited by 36
Prescription, over-the-counter (OTC), herbal, and other treatments and preventive uses for COVID-19
Yáñez, J. A., Chung, S. A., Román, B. R., Hernández-Yépez, P. J., García-Solórzano, F. O., Del-Aguila-Arcentales, S., Inga-Berrospi, F., Mejia, C. R., & Álvarez-Risco, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85780-2.00001-9 · Cited by 32
Socioeconomic factors associated with poor medication adherence in patients with type 2 diabetes
Ekenberg, M., Qvarnström, M., Sundström, A., Martinell, M., & Wettermark, B. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03571-8 · Cited by 30
Current Pharmacological Treatment of Type 2 Diabetes Mellitus in Undocumented Migrants: Is It Appropriate for the Phenotype of the Disease?
Fiorini, G., Cortinovis, I., Corrao, G., Franchi, M., Pincelli, A. I., Perotti, M., Rigamonti, A. E., Sartório, A., & Cella, S. G. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17218169 · Cited by 23
Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon‐like peptide‐1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow‐Up Registry
Jung, H., Tittel, S. R., Schloot, N. C., Heitmann, E., Otto, T., Lebrec, J., Pavel, M., & Lanzinger, S. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15038 · Cited by 23
Adherence to antidiabetic treatment among patients managed in primary care centres in Spain: the INTENSE study
Vlacho, B., Simarro, F. L., Mata‐Cases, M., Miravet-Jiménez, S., Escribano‐Serrano, J., Asensio, D., Cortés, X., & Franch‐Nadal, J. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.10.004 · Cited by 30
Prevalence and Factors Associated with Non-Adherence to Antidiabetic Medication Among Patients at Mbarara Regional Referral Hospital, Mbarara, Uganda
Faisal, K., Tusiimire, J., & Yadesa, T. M. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s343736 · Cited by 24
Patients' preferences for connected insulin pens: a discrete choice experiment among patients with type 1 and type 2 diabetes
Seo, J., Heidenreich, S., Aldalooj, E., Poon, J. L., Spaepen, E., Eby, E. L., & Newson, R. S. (2023) · The Patient - Patient-Centered Outcomes Research · doi:10.1007/s40271-022-00610-x · Cited by 19
Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study
Sigurgeirsson, B., Schäkel, K., Hong, C.-H., Effendy, I., Placek, W. J., Rich, P. A., Keefe, D. L., Bruin, G. J. M., Charef, P., Fu, R., et al. (2021) · Journal of Dermatological Treatment · doi:10.1080/09546634.2021.1902925 · Cited by 19
Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11
Van, J. T., Frías, J. P., Bonora, E., Raha, S., Meyer, J., Jung, H., Cox, D., Кониг, М., Peleshok, J. C., & Bethel, M. A. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01140-9 · Cited by 20
Treatment Persistence in Patients with Type 2 Diabetes Treated with Glucagon-like Peptide-1 Receptor Agonists in Clinical Practice in Sweden
Svensson, A., Toll, A., Lebrec, J., Miftaraj, M., Franzén, S., & Eliasson, B. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14276 · Cited by 17
Practical Guidance for Healthcare Providers on Collaborating with People with Type 2 Diabetes: Advancing Treatment and Initiating Injectable Therapy
BOEDER, S. C., Matamoros, D., & Mansy, C. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01330-z · Cited by 15
Adherence and Persistence to Basal Insulin Among People with Type 2 Diabetes in Europe: A Systematic Literature Review and Meta-analysis
Gimeno, E. J., Bøgelund, M., Larsen, S., Okkels, A., Reitzel, S. B., Ren, H., & Orozco‐Beltrán, D. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01559-w · Cited by 21
Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist
Edelman, S. V., Cassarino, D., Kayne, D. M., DEX, T. A., Li, X., & Pasquel, F. J. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.9.958 · Cited by 17
Depression but not non-persistence to antidiabetic drugs is associated with mortality in type 2 diabetes: A nested case-control study
Lunghi, C., Zongo, A., Tardif, I., Demers, É., Diendere, J. D., & Guénette, L. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108566 · Cited by 16
Needle-free jet injection of insulin glargine improves glycemic control in patients with type 2 diabetes mellitus: a study based on the flash glucose monitoring system
Kong, X., Luo, M.-H., Cai, L., Zhang, P., Yan, R., Hu, Y., Li, H., & Ma, J. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1863945 · Cited by 14
Disposal of Used Pens and Needles from Diabetes Patients` Perspective
Čatić, T., Gojak, R., & Djekic, D. (2020) · Materia Socio Medica · doi:10.5455/msm.2020.32.267-270 · Cited by 14
Efficacy and safety of a needle-free injector in Chinese patients with type 2 diabetes mellitus treated with basal insulin: a multicentre, prospective, randomised, crossover study
Xing, Y., Xie, X., Xu, J., Liu, J., He, Q., Yang, W., Zhang, N., Li, X., Wang, L., Fu, J., et al. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1649251 · Cited by 13
Patient perceptions of insulin therapy in diabetes self-management with insulin injection devices
Consoli, A., & Formoso, G. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02054-7 · Cited by 13
A cross-sectional study clarifying profiles of patients with diabetes who discontinued pharmacotherapy: reasons and consequences
Tominaga, Y., Morisky, D. E., & Mochizuki, M. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00778-7 · Cited by 12
Effects of a Digital Patient Empowerment and Communication Tool on Metabolic Control in People With Type 2 Diabetes: The DeMpower Multicenter Ambispective Study
Orozco‐Beltrán, D., Morales, C., Artola‐Menéndez, S., Brotons, C., Carrascosa, S., González, C., Baró, O., Verdugo, A. A., de Campos, K. F., Villarejo, M., et al. (2022) · JMIR Diabetes · doi:10.2196/40377 · Cited by 19
Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium–glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase‐4 inhibitor: A real‐world administrative database study in Japan
Kashiwagi, A., Shoji, S., Kosakai, Y., Koga, T., Asakawa, K., & Rokuda, M. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13952 · Cited by 12
Comparison of persistence and adherence between DPP-4 inhibitor administration frequencies in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study
Oh, A., Kisanuki, K., Nishigaki, N., Shimasaki, Y., Sakaguchi, K., & Morimoto, T. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1699519 · Cited by 11
Analysis of the Adherence and Safety of Second Oral Glucose-Lowering Therapy in Routine Practice From the Mediterranean Area: A Retrospective Cohort Study
Vlacho, B., Mata‐Cases, M., Mundet, X., Callol, J.-A. V. I., Real, J., Farré, M., Cos, X., Khunti, K., Mauricio, D., & Franch‐Nadal, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.708372 · Cited by 13
Issues Affecting Medication-Taking Behavior of People with Type 2 Diabetes in Indonesia: A Qualitative Study
Widayanti, A. W., Sigalingging, K. K., Dewi, F. P., & Widyakusuma, N. N. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s301501 · Cited by 8
Inhaled treprostinil vs iloprost: Comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension
Burger, C. D., Wu, B., Classi, P. M., & Morland, K. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.1.101 · Cited by 8
Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis
Zimner‐Rapuch, S., Divino, V. M., Norrbacka, K., Boye, K. S., Lebrec, J., Rosilio, M., DeKoven, M., & Guerci, B. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01055-5 · Cited by 9
Self-citation
Behavioral Sciences in the Optimization of Pharmacological and Non-Pharmacological Therapy for Type 2 Diabetes
Lopes, A. C., Roque, F., Morgado, S., Dinis, C., Herdeiro, M. T., & Morgado, M. (2021) · Behavioral Sciences · doi:10.3390/bs11110153 · Cited by 11
Enhanced learning and retention of medical information in Alzheimer’s disease after differential outcomes training
Molina, M., Carmona, I., Fuentes, L. J., Plaza, V., & Estévez, Á. F. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231578 · Cited by 8
Changes in diabetes prescription patterns following Affordable Care Act Medicaid expansion
Gemelas, J. C., Marino, M., Valenzuela, S. H., Schmidt, T. D., Suchocki, A., & Huguet, N. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002135 · Cited by 7
Safety, Tolerability, and Proof-Of-Concept Study of OKV-119, a Novel Exenatide Long-Term Drug Delivery System, in Healthy Cats
Klotsman, M., Adin, C. A., Anderson, W. H., & Gilor, C. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.661546 · Cited by 8
Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria
Ito, S., Chetlapalli, K., Wang, D., Potnis, K. C., Richmond, R., Krumholz, H. M., Lee, A. I., Cuker, A. C., & Goshua, G. (2024) · Blood · doi:10.1182/blood.2024025176 · Cited by 8
Treatment-Related Attributes of Diabetes Therapies and How People with Type 2 Diabetes Report Their Impact on Indicators of Medication-Taking Behaviors
Sims, T. J., Boye, K. S., Robinson, S. J., & Kennedy‐Martin, T. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s367046 · Cited by 8
Increased Healthcare Resource Use and Costs After Discontinuation of Liraglutide in Patients with Type 2 Diabetes from a Commercial- and Medicaid-Insured Claims Database
Uzoigwe, C., Noone, J. M., Liang, Y. M., Ali, S. N., & Gamble, C. L. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01322-z · Cited by 5
Treatment modification patterns of glucose-lowering agents in Saudi Arabia: A retrospective real-world data analysis
Alfakhri, A., Almadani, O. A., Althunian, T. A., Alrwisan, A. A., Badreldin, H. A., & Albogami, Y. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111770 · Cited by 5
Effect of fixed-ratio insulin combinations on adherence in type 2 diabetes: Systematic review
Elamin, M., & Barnish, M. S. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103072 · Cited by 5
Patient Adherence: Challenges, Myths, and Realities
Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_27 · Cited by 6
Complementary medicine use and its cost in Australians with type 2 diabetes: the Fremantle Diabetes Study Phase II
Yarash, T., Sharif, I., Masood, F., Clifford, R. M., Davis, W. A., & Davis, T. M. E. (2019) · Internal Medicine Journal · doi:10.1111/imj.14437 · Cited by 5
Antidiabetic medication use in commercially insured children and adolescents in the United States from 2004 to 2019
Sun, J. W., Hernández–Dı́az, S., Bourgeois, F. T., Haneuse, S., Brill, G. E., Bateman, B. T., & Huybrechts, K. F. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14237 · Cited by 5
Once-weekly Basal Insulin Fc versus daily insulin degludec for glycemic control in diabetes: a systematic review, meta-analysis, and meta-regression
Raja, S., Raja, A., Ali, A., & Asghar, M. S. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01602-y · Cited by 4
Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE)
Amamoo, J. J., Doshi, R., Noone, J., Xie, L. Y., Gamble, C. L., Guevarra, M., Divino, V. M., Chen, J., & King, A. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01721-y · Cited by 4
Persistence with once-weekly glucagon-like peptide 1 receptor agonist therapy decreases the risk of major adverse cardiovascular events: A retrospective analysis of patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease
Dunn, T. J., Zhu, Y., Gronroos, N. N., Xie, L., Sargent, A., Gamble, C. L., & Billings, L. K. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112162 · Cited by 4
“Negotiating a new normality” - a longitudinal qualitative exploration of the meaning of living with an open surgical wound
Pađen, L., Griffiths, J., & Cullum, N. A. (2022) · International Journal of Qualitative Studies on Health and Well-Being · doi:10.1080/17482631.2022.2123932 · Cited by 4
Obstacles to treatment retention in opioid use disorder: An international substance use disorder treatment worker survey
Jones, M., Guirguis, A., Watkins, A. J., Bradshaw, C., Mohamed, L., & Schifano, F. (2023) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2882 · Cited by 4
Perceived Future Outcomes of Unsuccessful Treatment and Their Association with Treatment Persistence Among Type-2 Diabetes Patients: A Cross-Sectional Content Analysis
Hidaka, T., Suzuki, R., Hashimoto, K., Inoue, M., Terada, Y., Endo, S., Kakamu, T., Gunji, M., Abe, K., & Fukushima, T. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01433-1 · Cited by 4
Assessment of basal insulin adherence using 2 methodologies among Texas Medicaid enrollees with type 2 diabetes
Zhang, H., Barner, J. C., Moczygemba, L. R., & Rascati, K. L. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.11.1434 · Cited by 5
What Is the Role of Basal Weekly Insulin in Clinical Practice? The State of the Art
Argano, C., Priola, L., Manno, F., & Corrao, S. (2024) · Biomedicines · doi:10.3390/biomedicines12040900 · Cited by 3
Comparison of Nurse Practitioner and Physician Management of Diabetes in Japan
Shozuhara, T., & Suzuki, M. (2024) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2024.105130 · Cited by 3
Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)
Edelman, S. V., Goldman, J. D., Malone, D. C., Preblick, R., Munaga, K., Li, X., Gill, J., & Gangi, S. (2023) · Clinical Diabetes · doi:10.2337/cd22-0096 · Cited by 3
Persistence of Weekly Injectable Semaglutide Use in Patients with Diabetes Mellitus and Obesity: A Retrospective Follow-Up in Colombia
Machado-Duque, M. E., Gaviria-Mendoza, A., Valladales-Restrepo, L. F., & Machado-Alba, J. E. (2025) · Drugs - Real World Outcomes · doi:10.1007/s40801-025-00518-6 · Cited by 2
Effect of initial combination therapy vs. step-therapy on adherence and persistence in drug naïve type 2 diabetes patients
Majd, Z., Chen, H., Johnson, M. L., Birtcher, K. K., Serna, O., Fatima, B., & Abughosh, S. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109080 · Cited by 2
Effects of using a mobile app to improve medication adherence and glycated hemoglobin in type 2 diabetes: A before-after study
Bakhtiari, F., Sajedi, F., Etminaniesfahani, M., & Rangchian, M. (2025) · International Journal of Risk & Safety in Medicine · doi:10.1177/09246479251377937 · Cited by 2
Effects of digital and remote exercise interventions on HbA1c in type 2 diabetes: a systematic review and network meta-analysis
Gao, S., Yan, M., Ding, H., & Jiang, L. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02267-1 · Cited by 2
Experimental and numerical study of solid needle insertions into human stomach tissue
Friis, S. J., Hansen, T. S., Olesen, C., Poulsen, M., Gregersen, H. N., & Nygaard, J. V. (2024) · Journal of the mechanical behavior of biomedical materials/Journal of mechanical behavior of biomedical materials · doi:10.1016/j.jmbbm.2024.106832 · Cited by 2
Investigating the Metabolic Benefits of Magnetic Mitohormesis in Patients with Type 2 Diabetes Mellitus
Tseng, F. S., Lim, G. H., Bee, Y. M., Lee, P. C., Tai, Y. K., Franco‐Obregón, A., & Tan, H. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186413 · Cited by 2
Real-world Patient characteristics, Treatment Patterns and Costs in Relapsing Multiple Sclerosis Patients Treated With Glatiramer acetate, Dimethyl Fumarate Or Teriflunomide in Germany
Ziemssen, T., Kurzeja, A., Muresan, B., Haas, J. S., Alexander, J., & Driessen, M. T. (2021) · Neurodegenerative Disease Management · doi:10.2217/nmt-2021-0031 · Cited by 2
Survey Reveals Patient and Health Care Provider Experiences and Challenges With the Use of High Doses of Basal Insulin
Goldman, J. D., Angueira-Serrano, E., Gonzalez, J. S., Pang, C., Tait, J., & Edelman, S. V. (2022) · Clinical Diabetes · doi:10.2337/cd22-0062 · Cited by 3
Insulin Delivery: An Evolution in the Technology
Kesavadev, J., Krishnan, G., & Benny, N. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_69 · Cited by 2
A Survey of Public Preferences on Repeat Dispensing
Lee, Y. M., Kim, D., Lee, E., & Sohn, H. S. (2024) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2024.34.1.30 · Cited by 2
Persistence of GLP-1 RA in combination with basal insulin among adults with type 2 diabetes in Canada
Abitbol, A., Siemens, R. L., Nightingale, N. M., Stewart, J. A., Toutounji, M.-J., & Goldenberg, R. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108920 · Cited by 1
How the Salutogenic Pattern of Health Reflects in Type 2 Diabetes Mellitus: A Narrative Review
Mijač, S., Vitale, K., Lončarek, K., & Slivšek, G. (2025) · Diabetology · doi:10.3390/diabetology6110124 · Cited by 1
Primary Non-Adherence to Electronic Prescriptions in Lithuania, 2018–2024: Nationwide Prevalence, Factors, and Regional Variation
Butrimaitė, V., Blockytė, M., Kazlauskaitė, J. A., Lasys, T., & Kubilienė, L. (2026) · Pharmacoepidemiology · doi:10.3390/pharma5030033 · Cited by 1
Effect of Baseline Characteristics on Hypoglycaemia Risk with Insulin Glargine 100 U/mL: Post Hoc Analysis of the BEYOND 7 Study
Wan, H., Wen, B., Wang, Y., Wang, J., Zhang, Y., Ning, T., Duan, B., Li, Y., Feng, W., Zhang, X., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01112-z · Cited by 1
Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan
Kadowaki, T., Inagaki, N., Watada, H., Sasaki, K., Mori‐Anai, K., Iwasaki, T., & Teranishi, T. (2022) · Advances in Therapy · doi:10.1007/s12325-021-02038-5 · Cited by 1
Predictors of success and failure in achieving glycemic control targets in patients with type 2 diabetes on basal insulin: review of the real-world evidence studies
Klimontov, V. V. (2022) · Diabetes Mellitus · doi:10.14341/dm12950 · Cited by 1
Insulin treatment adherence in type 2 diabetes mellitus patients: Literature review
Oktavia, A. D., & Muhlisin, A. (2024) · Open Access Research Journal of Science and Technology · doi:10.53022/oarjst.2024.10.2.0038 · Cited by 1
An assessment of treatment satisfaction, adverse effects, cost of treatment among patients with type 2 diabetes for semaglutide when compared to liraglutide: a hospital-based cross-sectional study
Pandey, S., Kakkar, A. K., Bhadada, S. K., & Ray, S. (2025) · Discover Public Health · doi:10.1186/s12982-025-00509-6 · Cited by 2
Thrice-Weekly Insulin Degludec Versus Once-Daily Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Kamrul-Hasan, A. B. M., Borozan, S., Fernandez, C. J., Dutta, D., Nagendra, L., & Pappachan, J. M. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.0716 · Cited by 1
Factors Associated With Non-Adherence To Antidiabetic Medication Among Patients at Mbarara Regional Referral Hospital, Mbarara, UgandaPreprint
Faisal, K., Yadesa, T. M., & Tusiimire, J. (2021) · Research Square · doi:10.21203/rs.3.rs-571953/v1 · Cited by 1
Implementing a Basal-Bolus Insulin Regimen Via a Manual Insulin Pump Device
Stearns, H. (2020) · Digital USD (University of San Diego) · doi:10.22371/07.2020.008
Efficacy of dulaglutide: an evidence-based review of its potential indications
Biryukova, E. V., & Solovyeva, I. V. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-7-18-30
Satisfaction, Preference and Injection Habits of Switching to 200 Units/ml Insulin Lispro Pen from 100 Units/ml: A Patient Survey in Germany
Chen, J., Williams, P. R., Perez‐Nieves, M., de Oliveira, C. P., Spaepen, E., Osumili, B., Poon, J. L., Schloot, N. C., Thun, B., & Blüher, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01150-7
Using 17th century medication for modern diabetes management: Doctors’ perceptions of self-medication practices – A qualitative study
Puvvada, R. K., Tang, C. Y., Thomas, J., Kay, M., Higgs, P., Jois, M., Madhan, R., & Gupta, S. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-022-01154-5
Ambiente hospitalario, funcionamiento familiar y afrontamiento activo como predictores de la adherencia al tratamiento farmacológico en pacientes con diabetes mellitus tipo 2
Soto, N. Y. T., Fernández, J. A. M., Armadillo, M. D. L. R., Fernández, I. A. M., Villalobos, H. A. P., Perry, S. D. B., & Lara, G. A. S. (2023) · Acta Universitaria · doi:10.15174/au.2023.3753 · Cited by 2
Insulin Icodec: A Silver Lining to the Diabetic Cloud
Thomas, M., Matreja, P. S., Prakash, J. S., & Singh, N. K. (2024) · International Journal of Human and Health Sciences (IJHHS) · doi:10.31344/ijhhs.v8i1.615
Overdose, personality correlates and treatment utilization in opioid use disorder
Jones, M. (2024) · doi:10.23889/suthesis.66936
Adherence and persistence rates for antidiabetic treatments in type 2 diabetes: a real-world study in an Italian region
Romagnoli, A., Savoia, M., Papini, G., Caprodossi, A., & Bartolini, F. (2025) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2024-004383 · Cited by 2
Telemedicine-Enabled Blood Glucose Monitoring as an Effective Strategy for Reducing Hypoglycaemia Risk in Diabetes
Kanwar, J., Shah, U. N., & Dawar, S. (2023) · Seminars in Medical Writing and Education · doi:10.56294/mw2023135
Mechanobiology of gastric needle insertions: a combined experimental and numerical study
Friis, S. J., Hansen, T. S., Poulsen, M., Kvist, P. H., Petersen, A., Gregersen, H. N., & Nygaard, J. V. (2025) · Biomechanics and Modeling in Mechanobiology · doi:10.1007/s10237-025-01986-z
Causal Mechanism Model for the Nursing Diagnosis of People Susceptible to an Imbalanced Blood Glucose Pattern
Lopes, R. O. P., Brandão, M. A. G., Gomes, E. D. S., & Barbosa, J. C. D. A. (2025) · Nursing Forum · doi:10.1155/nuf/4956038
Psychosocial factors and patient experience associated with diabetes treatment discontinuation: a cross-sectional study in Japan
Kuwabara, Y., Taniguchi, S., Hosoda-Urban, T., Son, D., Kinjo, A., Kim, H., Kaneda, Y., & Osaki, Y. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-103345
Impact of telehealth nutrition therapy on costs and utilization in type 2 diabetes & obesityPreprint
Shanmugam, P., Adams, R. N., Athinarayanan, S. J., Wolfberg, A., & Ballreich, J. M. (2025) · medRxiv · doi:10.1101/2025.11.09.25339829
Use of Fixed Ratio Combinations to Improve Glycemic Control in Individuals with Type 2 Diabetes: Experts’ Opinion from the Gulf Region
Hassanein, M. M., Alessa, T., Hafidh, K., Alzubaidi, L. M. Y., Jallo, M. K. I., Slail, F. Y. A., Elbadawi, H., & Malik, R. A. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01824-6
Persistence of fixed-dose combinations including dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes in Japan: analysis using a claims database
Kaku, K., & Naito, Y. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2649814
PHARMACOECONOMIC AND CLINICAL ANALYSIS OF ORAL HYPOGLYCEMIC DRUG USE IN TYPE 2 DIABETES MELLITUS IN PRIMARY HEALTH CARE FACILITIES IN AKTOBE, KAZAKHSTAN
Kaibagarova, I., Ablakimova, N., Smagulova, G., Мавлюдова, Н. М., Mussina, A. Z., Ovsiannikova, A. N., Sartayeva, A., & Zhamaliyeva, L. M. (2026) · Ġylym men densaulyķ saķtau. · doi:10.34689/sh.2026.28.1.006 · Cited by 1
Comparison of the intestinal permeation enhancers, SNAC and C₁₀, for oral peptides : biophysical, in vitro and ex vivo studies
Twarog, C. (2020) · theses.fr (ABES) · doi:10.70675/64939fcdzc6d7z4c62z9ea5zd405e5379fb7 · Cited by 1

Authors: Guerci, B., Chanan, N., Kaur, S., Jasso-Mosqueda, J. G., & Lew, E.
Affiliations: Inserm (FR)
Sanofi (France) (FR)
Corresponding author: Guerci, Bruno
ORCID: Guerci, Bruno
Lew, Elisheva
Venue: Diabetes Therapy
Publisher: Springer Science and Business Media LLC
Published: 2019-03-08
Volume: 10
Issue: 2
Pages: 437-449
ISSN: 1869-6953 (ISSN-L)
1869-6961
DOI: 10.1007/s13300-019-0590-x
PMC: PMC6437240
OpenAlex: W2922388296
Cited by: 106
References: 65
Citations by year: 2026: 10 · 2025: 17 · 2024: 11 · 2023: 12 · 2022: 16 · 2021: 23 · 2020: 14 · 2019: 3
FWCI: 3.56
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc
creativecommons.org/licenses/by-nc/4.0 (tdm)
creativecommons.org/licenses/by-nc/4.0 (vor)
Locations: Diabetes Therapy (publishedVersion, cc-by-nc)
Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
PubMed Central (publishedVersion, cc-by-nc)
PubMed (publishedVersion)
Funders: Sanofi
Topics: Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords: type 2 diabetes, treatment persistence, medication adherence, glycemic control, medication burden, insulin pen devices, drug delivery systems, patient expectations, adverse drug reactions, hypoglycemia, health care costs, real-world evidence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lack of Treatment Persistence and Treatment Nonadherence as Barriers to Glycaemic Control in Patients with Type 2 Diabetes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks